Measuring frailty in patients with severe aortic stenosis: a comparison of the Edmonton frail scale with modified fried frailty assessment in patients undergoing transcatheter aortic valve replacement

Francisco J Romeo1,#, Maximiliano Smietniansky2, Mariela Cal2, Cristian Garmendia1, Juan M Valle Raleigh1, Ignacio M. Seropian1, Mariano Falconi3, Pablo Oberti3, Vadim Kotowicz3, Carla R. Agatiello1, Daniel H Berrocal1

1Division of Interventional Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
2Division of Internal Medicine and Geriatrics, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
3Division Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
4Division of Cardiovascular Surgery, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

J Geriatr Cardiol 2020; 17: 441–446. doi:10.11909/j.issn.1671-5411.2020.07.001

Keywords: Aortic stenosis; Frailty; Transcatheter aortic valve replacement

Frailty is generally defined as a clinical syndrome of decreased physiologic reserve which drives to increased vulnerability and susceptibility to different stressors together with poor recovery to homeostasis.[1] The relevance of frailty status in a wide range of prospective cohorts is mostly related to an increasing burden in both mortality, hospital re-admissions, disability, and falls.[2,3]

In aortic stenosis (AS) population, the spectrum of frail patients significantly differs according to which frailty scale is used. Scales such as Rockwood Frailty Index,[4] Canadian Study of Health and Aging,[5] Katz ADL,[6] 6 min walk test,[7] up and go,[8] gait speed[9] have been described for improving risk stratification in transcatheter aortic valve replacement (TAVR) patients alone or in combination. More than 25 subjective or objective frailty markers have been developed but because of a lack of consensus, there is variability among studies and confusion about which marker to use.

The Modified Fried Frailty Assessment (MFFA) has been widely validated in different clinical scenarios and, in TAVR, has shown incremental prognostic value for functional decline including discharge to a rehabilitation facility after TAVR[10] and 1-year mortality.[4–11]

However, the assessment involves five domains and requires special equipment, though hard to apply in clinical practice for cardiologists involved in the care of valvular patients.

The Edmonton Frail Scale (EFS), a simple frail assessment that involves 10 questions and one physical assessment (‘timed up and go’) were recently described in a small cohort of TAVR patients identifying patients likely to experience longer hospital stays.[12] The aim of this clinical experience sought to compare the prevalence of frailty using the two scales, and agreement between them.

A retrospective analysis of 128 patients who underwent TAVR at an Argentinean academic hospital from July 2014 to July 2018 was performed. All patients met criteria for severe AS defined by the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.[13]

Ours is a tertiary care academic medical center in which all possible pre-TAVR candidates are discussed by a multidisciplinary heart valve team (cardiac surgeons, interventional cardiologists, cardiologists specialized in multimodality imaging and geriatricians) on a weekly basis. Final decisions regarding TAVR, surgical aortic valve replacement (SAVR) or futility patients are integrated into a core clinical discussion with frailty assessments, pre-TAVR multislice computed tomography (MSCT) measurements, cardiac biomarkers, and echocardiographic data.

Patient comorbidities were collected using the definitions provided by the STS data collection system.[14]

Frailty status was assessed by seven trained geriatricians using a MFFA which incorporated five domains of frailty: unintentional weight loss, exhaustion, muscle weakness, slowness while walking and low levels of activity. Each domain was scored individually in a binary fashion as normal or summed to generate a frailty score. We classified patients with a frailty score of ≥ 3/5 as frail, whereas those
with a score of 1-2/5 were classified as pre-frail, and those with a score of 0/5 were classified as non-frail.[1]

Each frailty domain was scored by commonly accepted methods of the MFFA. Patients with self-reported unintentional weight loss (5% of body weight lost unintentionally in the prior year) were considered as “shrinking”.

We measured 5-m gait speed (the time required for the patient to complete a 5-m walk test), and we defined slowness as a 5-m gait speed slower than the twentieth percentile from a cohort of over 5,000 community-dwelling adults > 65 years stratified by gender and height.[1] Grip strength for defining sarcopenia (i.e. “weakness”) was not evaluated due to the risk of syncope in this population. However, we used the SARC-F, a questionnaire with five questions, which has high specificity, albeit low sensitivity, to identify patients with sarcopenia.[15–17]

Finally, we assessed functional performance using the Katz Index of Independence in Activities of Daily Living (ADL) scale which is a patient-reported 6-point scale measuring dependence with 6 ADLs (bathing, dressing, hygiene, mobility, continence, and feeding). Congruous with previous reports using the Katz ADL scale, we defined declined functional performance as the presence of any disability (any score < 6).

As previously mentioned, the EFS comprised 10 questions and one physical assessment (“timed up and go”) performed by the same team of geriatricians. The EFS assesses nine domains of frailty (cognition, general health status, functional independence, social support, medication usage, nutrition, mood, continence, and feeding). Congruous with previous reports using the Katz ADL scale, we defined declined functional performance as the presence of any disability (any score < 6).

As shown in Figure 1, according to MFFA, 54/130 (40%) patients were frail, 49/130 (38%) patients were pre-frail and 28/130 (22%) were non-frail. Thirty-day outcomes were very similar between the frail and non-frail groups according to MFFA. Ten (7%) patients died within 30 days of undergoing TAVR. Of these, seven were non-frail (9% of the non-frail group) and three were frail (5% of the frail group).

As shown in Figure 2, according to EFS, 39/130 (30%) patients were frail, 43/130 (34%) patients were vulnerable and 46/130 (36%) patients were non-frail. Thirty-day outcomes were very similar between the frail and non-frail groups according to EFS. From the total of 10 patients who died within 30 days after TAVR, eight patients were classified as non-frail (8% of the non-frail group) and two were frail (5% of the frail group).

Finally, according to EFS, the median (IQR) LOS of the surviving to discharge patients was 5 days for non-frail and 4 days for the frail group, respectively (P = NS).

As shown in Figure 2, according to EFS, 39/130 (30%) patients were frail, 43/130 (34%) patients were vulnerable and 46/130 (36%) patients were non-frail. Thirty-day outcomes were very similar between the frail and non-frail groups according to EFS. From the total of 10 patients who died within 30 days after TAVR, eight patients were classified as non-frail (8% of the non-frail group) and two were frail (5% of the frail group).

Finally, according to EFS, the median (IQR) LOS of the surviving to discharge patients was 5 days for non-frail and 4 days for the frail group, respectively (P = NS). There was fair to moderate agreement between methods for determining which participants were frail [0.40 (0.084), P = 0.001].

In this single-center experience of elderly patients undergoing TAVR, the prevalence of frailty was 40% according to MFFA, and 30% according to the EFS. Of note, the EFS was validated in the hands of non-specialists who had no formal training in geriatric care. Thus, the EFS has the potential
Table 1. Baseline characteristics.

|                          | Total (n = 130) | Alive (n = 113) | Deceased (n = 17) | P-value |
|--------------------------|----------------|----------------|------------------|---------|
| Age, yrs                 | 84 (80–87)     | 84 (81–87)     | 84 (79–87)       | 0.86    |
| Men                      | 56 (43%)       | 50 (44.2%)     | 6 (35.2%)        | 0.48    |
| BMI, kg/m²               | 27 (24–32)     | 27 (23–32)     | 28 (25–32)       | 0.38    |
| Hypertension             | 118 (90.7%)    | 102 (90.2%)    | 16 (94.1%)       | 0.60    |
| Diabetes mellitus        | 28 (21.5%)     | 23 (20.3%)     | 5 (29.4%)        | 0.39    |
| Coronary artery disease  | 64 (49.2%)     | 55 (48.6%)     | 9 (52.9%)        | 0.74    |
| Coronary artery stent    | 36 (27.6%)     | 30 (26.5%)     | 6 (35.2%)        | 0.46    |
| Coronary artery bypass surgery | 19 (14.6%)   | 17 (15%)       | 2 (11.7%)        | 0.72    |
| Peripheral artery disease| 34 (26.1%)     | 28 (24.7%)     | 6 (35.2%)        | 0.35    |
| Chronic obstructive pulmonary disease | 14 (10.7%) | 11 (9.7%)     | 3 (17.6%)        | 0.32    |
| Chronic kidney disease   | 45 (34.6%)     | 40 (35.3%)     | 5 (29.4%)        | 0.65    |
| Hemoglobin, mg/dL        | 12.4 (11.4–13.5) | 12.5 (11.6–13.5) | 11.2 (10.6–12.7) | 0.04    |
| Atrial fibrillation or flutter | 33 (25.3%)   | 30 (26.5%)     | 3 (17.6%)        | 0.43    |
| NYHA class 3 or 4        | 39 (30%)       | 32 (28.3%)     | 7 (41.1%)        | 0.28    |
| Euroscore II             | 3 (1.9–4.6)    | 2.9 (1.9–4.5)  | 3.5 (2.6–6.7)    | 0.002   |
| STS-predicted 30-day operative mortality, % | 3.4 (2.5–5)    | 3.1 (2.2–4.9)  | 5.5 (4–8.9)      | 0.002   |
| NT pro-BNP, ng/dL        | 877 (405–2207) | 849 (377–2440) | 1412 (796–1871)  | 0.86    |
| Left ventricular ejection fraction, % | 56 (55–65)    | 55 (56–65)     | 60 (55–65)       | 0.97    |
| Aortic valve area, cm²   | 0.79 (0.67–0.90) | 0.80 (0.68–0.90) | 0.69 (0.64–0.94) | 0.43    |
| Trans-femoral TAVR       | 96 (73.8%)     | 82 (72.5%)     | 14 (82.3%)       | 0.39    |
| Transapical TAVR         | 34 (26.2%)     | 31 (27.5%)     | 3 (17.7%)        |         |

Categorical variables presented as n (%) with P-value indicating result of chi-square test between frailty groups. Continuous variables presented as median (IQR) with P-value indicating result of 1-way analysis of variance between frailty groups. BMI: body mass index; IQR: interquartile range; NYHA: New York Heart Association; STS: Society of Thoracic Surgeons; TAVR: trans-catheter aortic valve replacement.

Table 2. Frailty scales and geriatric domains.

|                          | Total (n = 130) | Alive (n = 113) | Deceased (n = 17) | P-value |
|--------------------------|----------------|----------------|------------------|---------|
| Fried, 0 to 5            | 2 (1–3)        | 2 (1–3)        | 2 (1–3)          | 0.98    |
| Edmonton, 0 to 17        | 6 (4–8)        | 6 (4–8)        | 6 (4–8)          | 0.72    |
| Timed Up and Go test, s  | 13.4 (11–17)   | 13.9 (10.7–17.1) | 12.2 (11.2–15.5) | 0.39    |
| Gait speed, m/s          | 0.62 (0.48–0.79) | 0.62 (0.48–0.80) | 0.62 (0.51–0.71) | 0.78    |
| Charlson score           | 2 (1–3)        | 2 (1–3)        | 2 (1–3)          | 0.22    |
| Weight loss              | 24 (18.4)      | 21 (18.5)      | 3 (17.6)         | 0.84    |
| Cognitive impairment (Mini-Cog) | 3 (1–4)    | 2 (1–4)        | 2 (1–3)          | 0.48    |
| Depressed mood (PHQ-2)   | 0 (0–1)        | 0 (0–1)        | 1 (0–2)          | 0.01    |
| ADL disability           | 6 (5–6)        | 6 (5–6)        | 5 (4–6)          | 0.22    |
| IADL disability          | 7 (5–8)        | 7 (5–8)        | 6 (5–8)          | 0.74    |

Data are presented as median (IQR) with P-values indicating result of one-way analysis of variance between frailty groups. ADL: activities of daily living; IADL: independent activities daily living; IQR: interquartile range.

as a practical and clinically meaningful measure of frailty in a variety of settings including pre-TAVR assessment. Despite we did not found differences in frailty prevalence between alive and deceased patients at follow-up, most of the patients were frail or pre-frail, i.e., “vulnerable”. It is important to mention that frailty is a dynamic concept that is
Figure 1. (A): Percentage of screened TAVR patients according to frailty status; (B): percentage of TAVR patients scoring 0 to 5 on adapted Fried’s frailty index. TAVR: transcatheter aortic valve replacement.

Figure 2. (A): Percentage of screened TAVR patients according to frailty status; (B): percentage of TAVR patients scoring 0 to 17 on adapted Edmonton frailty index. TAVR: transcatheter aortic valve replacement.

able to be reversed with adequate intervention. We believe our results may be influenced by the fact that patients with extreme frailty, severely impaired functional performance, dementia and less than a year of life expectancy were excluded from TAVR according to our comprehensive geriatric assessment.

The association of both EFS and MFFA with multidimensional geriatric conditions has already been studied showing an association with several geriatric conditions such as independence, drug assumption, mood, mental, functional and nutritional status.

In general, we found a similar distribution of cognition impairment, deficits in physical performance and comorbidities burden between alive and deceased patients at 1-year follow-up. However, deceased patients showed significantly higher rates of mood disorders. The influence of both cognitive impairment and depression on TAVR has not been conclusive in the literature.

There was a fair to moderate agreement between assessment methods in our cohort. These findings are similar to those reported by Pritchard, et al. who showed agreement between MFFA and other frailty assessment method (SPPB, i.e., Short Performance Physical Battery) and also Islam, et al. and Theou, et al. whom both showed agreement between MFFA and CFS, i.e., Clinical Frailty Scale. Although the EFS has been compared against the clinical impression of frailty by geriatric specialists appearing to be valid, reliable and feasible for routine use by non-geriatricians, there is no previous data in the literature comparing these two scales for frailty assessment neither agreement between them.

Given that physical activity expressed by the TUG and gait speed are important indicators of frailty, it is not surprising that agreement between the EFS and MFFA is fair to moderate. Our findings show that for identifying frail or pre-frail older adults, either method could be used, but consideration should be provided to other aspects specifically involving motor abilities.

Unfortunately, there is still a lack of consensus for a single frailty method in clinical practice. In this direction, in order to improve understanding of how frailty impacts survival, functionality, and quality of life in TAVR recipients, a protocol has been recently published for a systematic review which will surely shed light on this issue.

Our study has some limitations. Our data are derived from a retrospective, single-center experience, which limits the
external validity of our findings. Second, the sample size in our report is modest, which limits our ability to detect small but important differences in outcomes between groups. In this direction, because of the lack of statistically significant differences between frail and non-frail patients with mortality, we did not perform adjusted multivariate analysis. Moreover, it is probable that frail patients had more incidence of other important outcomes such as falls, disabilities and long-term functional decline which were not analyzed in this manuscript.

Finally, the hand grip test was not performed in the vast majority of the patients due to the risk of syncope regarding their clinical status (AS). Weakness in MFFA was then punctuated by geriatricians regarding other method (SARC-F questionnaire). Although the prevalence of frailty rates where similar to those reported in the literature, this limitation could influence our results.

In conclusion, the prevalence of frailty using both MFFA and EFS is similar to that reported in the literature. A fair to moderate agreement was estimated between methods.

Acknowledgements

Many thanks to the staff in our team who participated in the patient follow-up. All authors have no conflicts of interest to disclose.

References

1. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146–M156.
2. Clegg A, Young J, Iliffe S, et al. Frailty in elderly people. Lancet 2013; 381: 752–762.
3. Tom SE, Adachi JD, Anderson FA, et al. Frailty and fracture, disability, and falls: a multiple country study from the global longitudinal study of osteoporosis in women. J Am Geriatr Soc 2013; 61: 327–334.
4. Afilalo J, Lauck S, Kim DH, et al. Frailty in older adults undergoing aortic valve replacement: The FRAILTY-AVR Study. J Am Coll Cardiol 2017; 70: 689–700.
5. Kleczyński P, Dzwirz A, Bagienski M et al. Impact of frailty on mortality after transcatheter aortic valve implantation. Am Heart J 2017; 185: 52–58.
6. Puls M, Sobisak B, Blecchina M, et al. Impact of frailty on short- and long-term morbidity and mortality after transcatheter aortic valve implantation: Risk assessment by Katz Index of activities of daily living. EuroIntervention 2014; 10: 609–613.
7. Green P, Cohen DJ, Generoux P, et al. Relation between six-minute walk test performance and outcomes after transcatheter aortic valve implantation (from the PARTNER Trial). Am J Cardiol 2013; 112: 700–706.
8. Stortecy S, Schoenenberger A, Moser A, et al. Evaluation of multidimensional geriatric assessment as a predictor of mortality and cardiovascular events after transcatheter aortic valve implantation. JACC Cardiovasc Interv 2012; 5: 489–496.
9. Kano S, Yamamoto M, Shimura T, et al. Gait speed can predict advanced clinical outcomes in patients who undergo transcatheter aortic valve replacement insights from a Japanese multicenter registry. Circ Cardiovasc Interv 2017; 10: e005088.
10. Huded CP, Huded JM, Friedman JL, et al. Frailty Status and Outcomes after Transcatheter Aortic Valve Implantation. Am J Cardiol 2016; 117: 1966–1971.
11. Chauhan D, Haik N, Merlo A, et al. Quantitative increase in frailty is associated with diminished survival after transcatheter aortic valve replacement. Am Heart J 2016; 182: 146–154.
12. Koziol L, Khan, Frame A, et al. Use of the reported edmonton frail scale in the assessment of patients for transcatheter aortic valve replacement. a possible selection tool in very high-risk patients? J Geriatr Cardiol 2018; 15: 463–466.
13. Nishimura RA, Otto CM, Bonow RO, et al. AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2438–2488.
14. STS Adult Cardiac Surgery Database data collection forms and specifications. http://www.sts.org/STS-national-database/database-managers/adultcardiac-surgerydatabase/data-collection (accessed October 24, 2019).
15. Malmström TK, Miller DK, Simonsick EM, et al. SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle 2016; 7: 28–36.
16. Woo J, Leung J, Morley JE. Defining sarcopenia in terms of incident adverse outcomes. J Am Med Dir Assoc 2015; 16: 247–252.
17. Bahat G, Yilmaz O, Kiliç C, et al. Performance of SARC-F in regard to sarcopenia definitions, muscle mass and functional measures. J Nutr Health Aging 2018; 22: 898–903.
18. Rolfsen DB, Majumdar SR, Tsuyuki RT, et al. Validity and reliability of the Edmonton Frail Scale. Age Ageing 2006; 35: 526–529.
19. Partridge JSL, Judith SL, Fuller M, et al. Frailty and poor functional status are common in arterial vascular surgical patients and affect postoperative outcomes. Int J Surg 2015; 18: 57–63.
20. Morley JE, Vellas B, van Kan A, et al. Frailty consensus: a call to action. J Am Med Dir Assoc 2013; 14: 392–397.
21. Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged; the index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963; 185: 914–919.
22. Perna S, Francis MD, Bologna C, et al. Performance of Edmontor Frail scale on frailty assessment: its association with multi-dimensional geriatric conditions assessed with specific screening tools. BMC Geriatr 2017; 17: 2.
23 Akin S, Mazicioglu MM, Mucuk S, et al. The prevalence of frailty and related factors in community-dwelling Turkish elderly according to modified Fried Frailty Index and FRAIL scales. Aging Clin Exp Res 2015; 27: 703–709.
24 Buttery AK, Busch MA, Gaertner B, et al. Prevalence and correlates of frailty among older adults: findings from the German health interview and examination survey. BMC Geriatr 2015; 15: 22.
25 Pritchard J, Kennedy C, Karampatos S, et al. Measuring frailty in clinical practice: a comparison of physical frailty assessment methods in a geriatric outpatient clinic. BMC Geriatr 2017; 17: 264.
26 Islam A, Muir-Hunter SW, Speechley M, et al. Facilitating frailty identification: comparison of two methods among community-dwelling older adults. J Frailty Aging 2014; 3: 216–221.
27 Theou O, Brothers TD, Mitnitski A, et al. Operationalization of frailty using eight commonly used scales and comparison of their ability to predict all-cause mortality. J Am Geriatr Soc 2013; 61: 1537–1551.
28 Viana JU, Silva SL, Torres JL, et al. Influence of sarcopenia and functionality indicators on the frailty profile of community-dwelling elderly subjects: a cross-sectional study. Braz J Phys Ther 2013; 17: 373–381.
29 Li Z, Dawson E, Moodie J, et al. Frailty in patients undergoing transcatheter aortic valve implantation: a protocol for a systematic review. BMJ Open 2019; 9: e024163.